Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | MPO | P05164 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24243752 | 0.86 | HTR2A (0.48) | HTR2AMPOKDM4ESLC6A4CDK4 | |
| SCHEMBL30053780 | 0.85 | PRKAB2 (0.38) | ALDH1A1 | |
| SCHEMBL24243751 | 0.84 | KDM4E (0.50) | HTR2AMPOKDM4ESLC6A4CDK4 | |
| SCHEMBL29206542 | 0.81 | GPR84 (0.43) | — | |
| SCHEMBL29206503 | 0.81 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL30877835 | 0.81 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL30877836 | 0.81 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL24243764 | 0.80 | KDM4E (0.55) | HTR2AMPOKDM4ESLC6A4CDK4 | |
| SCHEMBL30622613 | 0.80 | KDM4E (0.55) | HTR2AMPOKDM4ESLC6A4CDK4 | |
| SCHEMBL25311099 | 0.79 | KDM4E (0.48) | HTR2AMPOKDM4ESLC6A4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055059-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4501407-A2 | SPECIFIC TRYPTAMINES FOR USE IN THE TREATMENT OF MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4084791-B1 | SPECIFIC TRYPTAMINES FOR USE IN THE TREATMENT OF MOOD DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240351983-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240317683-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4084791-A1 | SPECIFIC TRYPTAMINES FOR USE IN THE TREATMENT OF MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11440879-B2 | Methods of treating mood disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440879-B2 | Methods of treating mood disorders | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885MPO 2017/4885KDM4E 1141/4885 |
| US-20240351983-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885MPO 2017/4885KDM4E 1141/4885 |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885MPO 2017/4885KDM4E 1141/4885 |
| US-20260055059-A1 | METHODS OF TREATING MOOD DISORDERS | SDHB, SDHA, SORD | HTR2A 496/4885MPO 2186/4885KDM4E 1164/4885 |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885MPO 2017/4885KDM4E 1141/4885 |
| US-20240317683-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885MPO 2017/4885KDM4E 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.